Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected adults \>=18 years of age;~* currently on antiretroviral (ARV) therapy;~* previously treated with 2 or 3 different antiretroviral classes;~* HIV-1 Ribonucleic acid (RNA) \>=1,000 copies/mL;~* Cluster differentiation antigen four (CD4) lymphocyte count \>=200 cells/mm\^3;~* females of childbearing potential must be willing to use a reliable form of effective barrier contraception for the duration of the study and for 30 days after the last dose of study drug.~Exclusion Criteria:~* history of prior use of enfuvirtide or T-1249;~* women who are pregnant, breastfeeding or planning to become pregnant during the study;~* active, untreated opportunistic infection;~* patients on treatment interruption, or patients interrupting ARV therapy within 4 weeks of screening or during the screening period for reasons either than toxicity management.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ENF + HAART (Type: EXPERIMENTAL): Participants received Enfuvirtide (ENF) 90 mg administered by subcutaneous injection twice a day for up to 48 weeks in addition to an oral highly active antiretroviral treatment (HAART) regimen for up to 48 weeks.
- HAART (Type: ACTIVE_COMPARATOR): Participants received an oral highly active antiretroviral treatment (HAART) regimen, consisting of 3-5 antivirals for up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).